Reader Norm sent me this news item which alleges that sheer greed for excessive profits is causing one drug company (Genentech) to try to block a possible cure for macular degeneration (which can cause blindness) from being tested and approved, because the cost of this drug ($50 per dose) Avastin is forty times less that the alternative treatment Lucentis ($2,000 per dose) marketed by the same company.
The Plain Dealer also ran a story on the fact that the Cleveland Clinic ran a comparison test anyway and found that Avastin worked as well as Lucentis.
